Non-small cell lung cancer: The challenges of the next decade

Frontiers in Oncology

Volumn 1, Issue SEP, 2011, Pages

  Le Chevalier, Thierry ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878446216     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00029     Document Type: Article

References (35)

1. Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi A. T., III., Shepherd, F. A., Smith, C., Chen, Y., Livingston, R. B., Feins, R. H., Gandara, D. R., Fry, W. A., Darling, G., Johnson, D. H., Green, M. R., Miller, R. C., Ley, J., Sause, W. T., and Cox, J. D. (2009). Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374, 379-386.
2. Altorki, N., Lane, M. E., Bauer, T., Lee, P. C., Guarino, M. J., Pass, H., Felip, E., Peylan-Ramu, N., Gurpide, A., Grannis, F. W., Mitchell, J. D., Tachdjian, S., Swann, R. S., Huff, A., Roychowdhury, D. F., Reeves, A., Ottesen, L. H., and Yankelevitz, D. F. (2010). Phase II proof-of-concept study of Pazopanib monotherapy in treatment-naïve patients with stage I-II respectable non-small cell lung. J. Clin. Oncol. 28, 3131-3137.
3. Auperin, A., Le Pechoux, C., Pignon, J. P., Koning, C., Jeremic, B., Clamon, G., Einhorn, L., Ball, D., Trovo, M. G., Groen, H. J., Bonner, J. A., Le Chevalier, T., and Arriagada, R. (2006). Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann. Oncol. 17, 473-483.
4. Baumann, P., Nyman, J., Hoyer, M., Wennberg, B., Gagliardi, G., Lax, I., Drugge, N., Ekberg, L., Friesland, S., Johansson, K. A., Lund, J. A., Morhed, E., Nilsson, K., Levin, N., Paludan, M., Sederholm, C., Traberg, A., Wittgren, L., and Lewensohn, R. (2009). Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J. Clin. Oncol. 27, 3290-3296.
5. Burdett, S., Rydzewska, L. H., Tierney, J. F., and Pignon, J. (2011). Pre-operative chemotherapy improves survival and reduces recurrence in operable non-small cell lung cancer. Proc. WCLC.
6. Cappuzzo, F., Ciuleanu, T., Stelmakh, T., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., Klingelschmitt, G., Klughammer, B., and Giaccone, G. (2010). Erlotinib as maintenance treatment in advanced non-small-lung cancer: a multi-centre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 6, 521-529.
7. Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y. L., Bover, I., Begbie, S., Tzekova, V., Cucevic, B., Pereira, J. R., Yang, S. H., Madhavan, J., Sugarman, K. P., Peterson, P., John, W. J., Krejcy, K., and Belani, C. P. (2009). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374, 1432-1440.
8. Coate, L. E., John, T., Tsao, M. S., and Shepherd, F. A. (2009). Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 10, 1001-1010.
9. Delaney, G., Barton, M., Jacob, S., and Jalaludin, B. (2003). A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 4, 120-128.
10. th WCLC, 2009, abstract PRS3).
11. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2008). Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, GLOBOCAN. Lyon: International Agency for Research on Cancer. Available at: http://globocan.iarc.fr
12. Johnstone, D. W., Byhardt, R. W., Ettinger, D., and Scott, C. B. (2002). Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 54, 365-369.
13. Kamal, N. S., Soria, J. C., Mendiboure, J., Planchard, D., Olaussen, K. A., Rousseau, V., Popper, H., Pirker, R., Bertrand, P., Dunant, A., Le Chevalier, T., Filipits, M., and Fouret, P. (2010). MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin. Cancer Res. 16, 1206-1215.
14. Kim, E. S., Hirsch, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y. L., Li, L. Y., Watkins, C. L., Sellers, M. V., Lowe, E. S., Sun, Y., Liao, M. L., Osterlind, K., Reck, M., Armour, A. A., Shepherd, F. A., Lippman, S. M., and Douillard, J. Y. (2008). Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372, 1809-1818.
15. Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Aronson, S. L., Engelman, J. A., Shyr, Y., Khuri, F. R., Rudin, C. M., Garon, E. B., Pao, W., Schiller, J. H., Haura, E. B., Shirai, K., Giaccone, G., Berry, L. D., Kugler, K., Minna, J. D., and Bunn, P. A. (2011). Identification of driver mutations in tumor specimens from 1000 patients with adenocarcinoma: The NCI's Lung Cancer Mutation Consortium. ASCO. J. Clin. Oncol. 29 (suppl), [Abstract CRA 7506].
16. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., and Nukiwa, T. (2010). Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388.
17. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., and Fukuoka, M. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG 3405): an open label randomised phase 3 trial. Lancet Oncol. 11, 121-128.
18. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J. J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., and Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947.
19. Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., Stahel, R., Sabatier, L., Pignon, J. P., Tursz, T., Le Chevalier, T., and Soria, J. C. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991.
20. Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C. T., Ganul, V., Roh, J. K., Bajetta, E., O'Byrne, K., de Marinis, F., Eberhardt, W., Goddemeier, T., Emig, M., and Gatzemeier, U. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525-1531.
21. Rosell, R., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Cardenal, F., Garcia Gomez, R., Pallares, C., Sanchez, J. M., Porta, R., Cobo, M., Di Seri, M., Garrido Lopez, P., Insa, A., De Marinis, F., Corre, R., Carreras, M., Carcereny, E., Taron, M., and Paz-Ares, L. G. (2011). Erlotinib versus chemotherapy in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: interim results of the European Erlotinib versus chemotherapy (EURTAC) phase III randomized trial. J. Clin. Oncol. [Abstract 7503].
22. Rosell, R., Skrzypski, M., Jassem, E., Taron, M., Bartolucci, R., Sanchez, J. J., Mendez, P., Chaib, I., Perez-Roca, L., Szymanowska, A., Rzyman, W., Puma, F., Kobierska-Gulida, G., Farabi, R., and Jassem, J. (2007). BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2, e1129.
23. Rusch, V. R., Crowley, J. J., Giroux, D., Goldstraw, P., Im, J. G., Tsuboi, M., Tsuchiya, R., and Vansteenkiste, J. (2007). The IASLC lung cancer staging project: proposals for revision of the N descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 2, 603-612.
24. Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., and Johnson, D. H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550.
25. Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., and Shepherd, F. A. (2009). The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14, 253.
26. Seve, P., Lai, R., Ding, K., Winton, T., Butts, C., Mackey, J., Dumontet, C., Dabbagh, L., Aviel-Ronen, S., Seymour, L., Whitehead, M., Tsao, M. S., Shepherd, F. A., and Reiman, T. (2007). Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin. Cancer Res. 13, 994-999.
27. Shepherd, F. A., Johnston, M. R., Payne, D., Burkes, R., Deslauriers, J., Cormier, Y., de Bedoya, L. D., Ottaway, J., James, K., and Zee, B. (1998). Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Br. J. Cancer 78, 683-685.
28. Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabárbara, P., and Seymour, L. (2005). Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 353, 1739-1741.
29. Shepherd, F. A., and Rosell, R. (2007). Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J. Thorac. Oncol. 2, S68.
30. Simon, C. J., Dupuy, D. E., DiPetrillo, T. A., Safran, H. P., Grieco, C. A., Ng, T., and Mayo-Smith, W. W. (2007). Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 243, 268-275.
31. Stewart, L. A., Burdett, S., Tierney, J. F., and Pignon, J. (2007). Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J. Clin. Oncol. 25, 7552.
32. The National Lung Screening Trial Research Team. (2011). Reduced Lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395-409.
33. Tyagi, P., and Mirakhur, B. (2009). MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer 10, 371-374.
34. van Meerbeeck, J. P., Kramer, G. W., Van Schil, P. E., Legrand, C., Smit, E. F., Schramel, F., Tjan-Heijnen, V. C., Biesma, B., Debruyne, C., van Zandwijk, N., Splinter, T. A., and Giaccone, G. (2007). Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J. Natl. Cancer Inst. 99, 442-450.
35. Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A., and Bepler, G. (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356, 800-808.